European Immunotherapy Net

The central resource platform for healthcare professionals and patients, giving you the latest news and updates on all areas of immunotherapy.

European Immunotherapy Net

The European Immunotherapy Net brings you the latest news and updates on all areas of immunotherapy. This platform offers healthcare professionals, nurses and patients access to the best in scientific publications, research, continuing medical education and more via a digital community that nurtures a transparent exchange of ideas, information, and activities. Powered by the European Hematology Association.

Learn More

The challenge of COVID-19: EBMT recommendations for management of transplant and CAR T-cell therapy patients

Browse all scientific publications

Latest News

Immunotherapy Web Featured Images 25

EHA and EBMT join forces in the GoCART coalition to advance cellular therapy in Europe.

EHA joins EBMT in a newly founded GoCART coalition aimed at positioning Europe in the lead of the global cellular therapy field for hematological diseases. GoCART aims to promote patient access to novel cellular therapies and to contribute health and well-being through innovation by multi-stakeholder collaboration.


CAR T-Cell Research Surges

Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since the first such treatment received approval in 2017. Hundreds of trials are under way, 3 therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma (MM).

Immunotherapy Web Featured Images 27

Bispecific anti-CD20 and anti-CD19 CAR T Cell Therapy Shows Efficacy in B Cell Malignancies in Phase 1 Trial

Nirav N. Shah, MD, an associate professor at the Medical College of Wisconsin, discusses bispecific anti-CD20 and anti-CD19 chimeric antigen receptor (CAR) T cells in a phase 1 dose escalation and expansion trial (NCT03019055) for relapsed B cell malignancies.


European Immunotherapy Net: Together, we can make a difference.

At European Immunotherapy Net, we believe that working together is the key to driving positive change, and that is why we are asking you to join us. Let's work together in creating a dedicated immunotherapy resource platform that represents the highest level of professional knowledge, ultimately helping to provide the best care for patients. Learn more about how you can contribute.


Research Highlights

ImmunotherapyWebsite Nurses Patients 99

Scientific Publications

Browse our collection of scientific publications on Immunotherapy to learn more about the latest research and developments in the field.

Read more


EHA Research Grants support talented junior researchers in advancing their career, e.g. towards becoming the leader of a research group.

Read more
Education Higlights

Immunotherapy Web Featured Images 21

2nd European CAR T Cell Meeting (Jan 30 - Feb 1, 2020) Report

Sections: (1) The clinical landscape for CAR-T, and current developments in Europe, (2) The global efforts to improve CAR T-cell therapy and (3) Regulatory considerations and directions for the European CAR-T landscape

Read more
Immunotherapy Web Featured Images 1

EHA CAR-T Program

An eight-course program covering all aspects of CAR-T; mechanisms of action, the process of CAR-T manufacture and infusion, treatment of hematopoietic malignancies and patient selection, CRS, and other complications as well as ethics and consent, multidisciplinary care and regulatory aspects.

Read more
Patient Highlights

ImmunotherapyWebsite Nurses Patients 34


Whether you are a health care practitioner looking to expand your knowledge or a carer explaining immunotherapy to a child or its family for the first time, we are here to help.

Access resource library
ImmunotherapyWebsite Nurses Patients 33


While Immunotherapy has the power to change lives, it can be hard to find the information and support you need during treatment. 

Acess resource library
Nurses Highlights


Promising Response Rates Build Excitement for CAR T-Cell Therapy in Myeloma

CAR T-cell therapy is poised to transform the treatment paradigm of relapsed/refractory multiple myeloma now that multiple products are exhibiting high and complete response (CR) rates, said Faiz Anwer, MD, who added that further research may improve safety, prolong responses, and provide insight into resistance mechanisms.

Read more

CAR T-Cell Therapy: High Response Rates, High Toxicity Rates

CAR T-cell therapy has drastically changed the treatment landscape of patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) – a patient population that traditionally has been difficult to treat and had poor outcomes.

Read more